Indonesia’s $9B Chinese Fighter Jet Deal Shocks the World

Indonesia’s $9B Chinese Fighter Jet Deal Shocks the World

  • Indonesia will buy at least 42 Chinese Chengdu J-10C fighters (a ~$9 billion commitment in the 2026 budget), marking the country’s first major arms purchase from Beijing.
  • “They will be flying over Jakarta soon,” said Defense Minister Sjafrie Sjamsoeddin. The purchase is part of Indonesia’s Trisula Nusantara modernization push. Jakarta also ordered 42 French Dassault Rafales ($8.1B) and 48 Turkish KAAN jets as it replaces aging F-16s and Sukhois.
  • Shift to multipolar procurement: Experts note Indonesia’s “bebas-aktif” non-aligned policy means buying the best platforms regardless of origin [1]. Analyst Beni Sukadis warns that the J-10 deal “could be read as a shift in Indonesia’s security orientation amid China’s growing influence” in Southeast Asia. But many analysts emphasize Jakarta’s focus on capability and sovereignty over bloc allegiances [2].
  • Chinese view: PLA and Chinese officials praise the J-10’s performance. State media quotes a Chinese military researcher calling the J-10 “cost-effective” with outstanding radar and missiles, combat-proven in recent conflicts. China’s defense ministry says it is “willing to share the achievements of China’s equipment development with friendly countries” to promote regional stability.
  • Market impact: Western defense stocks held firm. Lockheed Martin (NYSE: LMT) closed around $495 on Oct. 17 [3] and Boeing (NYSE: BA) about $212 [4]. By contrast, Saab AB (Sweden; maker of the Gripen fighter) dropped ~4.4% to 461.9 SEK [5] on Oct. 17, as analysts note competition from Chinese jets. Tech analysis site TS2.tech observes Indonesia had been evaluating Saab’s Gripen, but had already locked in Rafales and eyed U.S. F-15s. The fighter jet market is heating up worldwide, with Pakistan, Iran and others showing interest in China’s J-10.
  • Next steps: The exact contract details and delivery schedule remain under wraps. Indonesian officials say budget approvals are done, but reports suggest the deal might be financed partly by loans. Deliveries could begin in the late 2020s, with pilot training in China by 2026 [6]. Jakarta insists this deal won’t undermine its ties with the U.S. or France – as one analyst notes, Indonesia is now buying Chinese jets and continuing Rafales and Turkish planes, “yet maintains ties with the United States” [7].

Indonesia’s abrupt pivot to Chinese fighters has captured global attention. Defense analysts say it underscores Jakarta’s insistence on strategic autonomy. “Foreign actors can spread disinformation, but at the end of the day, Indonesia buys what it chooses,” writes analyst Muhammad Zulfikar Rakhmat [8]. In practice, Jakarta is “quietly demonstrating that strategic autonomy is possible” – fielding the latest jets from East and West while balancing great-power pressures [9]. For now, Southeast Asian neighbors and global arms makers will be watching closely how this deal unfolds and how it reshapes the region’s airpower balance.

Sources: Official statements and budget documents; reporting from AP and The Diplomat [10]; expert analysis in Asia Times and FlightGlobal [11] [12]; market data from Reuters and Investing.com [13] [14]; industry commentary from TS2.tech.

Indonesia Setujui Pembelian Jet Tempur Canggih J-10C dari China Senilai Rp139 Triliun ✈️🇮🇩

References

1. asiatimes.com, 2. asiatimes.com, 3. www.investing.com, 4. www.investing.com, 5. www.reuters.com, 6. defencesecurityasia.com, 7. asiatimes.com, 8. asiatimes.com, 9. asiatimes.com, 10. thediplomat.com, 11. asiatimes.com, 12. www.flightglobal.com, 13. www.investing.com, 14. www.reuters.com

Stock Market Today

  • Evercore ISI Lifts Aflac Price Target to $111 Amid Mixed Broker Calls
    November 8, 2025, 11:42 AM EST. Evercore ISI raised Aflac (NYSE:AFL) target price from $110 to $111 but kept an underperform rating. The move comes as a mixed bag of broker calls: Barclays underweight with a $104 target; Piper Sandler overweight at $125; UBS trimmed to $111 with a neutral stance; Morgan Stanley raised to $113 with an equal weight rating; Keefe, Bruyette & Woods lifted to $110 with a market perform rating. MarketBeat shows a consensus of 3 Buy, 6 Hold, 2 Sell and an average target of $110.30. AFL traded about $114.11, up 0.4%, with a 50-day moving average of $108.84 and a 200-day at $105.69. Key metrics include a P/E near 25.9, ROE ~15%, debt/equity 0.33, and a 100 million share buyback approved. Near-term moves depend on earnings outlook and buyback execution.
  • Cardsmiths' Currency Series 5 Lets Collectors Redeem Real Bitcoin, Ethereum and Dogecoin
    November 8, 2025, 11:14 AM EST. Cardsmiths' Currency Series 5 introduces five cards redeemable for 1 full Bitcoin each, plus options for Ethereum, Litecoin, and Dogecoin. Priced from $37 for a 2-pack, crypto redemptions show up in roughly 1 of every 96 packs. The line also includes a non-redeemable 1/1 Bitcoin card and features collaborations with Gunship Revolution Studios, Jon McTavish, and Mr. Brainwash. Demand for Currency releases remains elevated, with collectors turning inexpensive packs into six-figure crypto payouts-examples include a $50 Holiday set yielding six figures and an August $13 pack valued around $115k. BitPay enables payments in BTC, ETH, DOGE, and USDC, and Cardsmiths says more Currency releases are coming.
  • Moffett Nathanson Lifts Warner Bros. Discovery Target to $26, Reiterates Buy (WBD)
    November 8, 2025, 11:12 AM EST. Moffett Nathanson raised Warner Bros. Discovery's price target from $23.00 to $26.00 per share and reiterated a Buy on the stock, signaling about a 14.93% upside from the prior close. Other analysts include Argus at $27, Guggenheim to $22 with a Buy, Wells Fargo to $21 (Equal Weight), Benchmark to $25 (Buy), and Bernstein to $16 (Market Perform). The street shows a mix: 3 Strong Buy, 13 Buy, 14 Hold; MarketBeat's consensus is Moderate Buy with a $20.35 target. WBD traded around $22.62, up 0.9%, on about 2.6 million shares vs. 48.6 million average. Quarterly results showed revenue $9.05B and EPS -0.06, with ROE near 2.1% and a 2% net margin.
  • MTL:CA Mullen Group AI-Generated Signals: Neutral Ratings and Buy/Sell Levels
    November 8, 2025, 11:10 AM EST. This update presents AI-generated signals and explicit levels for Mullen Group Ltd (MTL:CA). Key long ideas: buy near 13.49 with a target of 14.45 and a stop at 13.42. The short setup suggests selling near 14.45, targeting 13.49 with a stop at 14.52. November 8 ratings show Near, Mid, and Long views all as Neutral. Readers are directed to review the AI-generated signals for MTL:CA and the accompanying chart to gauge timing and risk. The plan reinforces disciplined risk management with clearly defined entry/exit points, while the overall stance remains Neutral, keeping execution-focused traders attentive.
  • CoreWeave: AI infrastructure darling or debt-fueled bubble on Wall Street
    November 8, 2025, 10:54 AM EST. CoreWeave, a major provider of AI infrastructure power, has become a stock-market darling as its data-centre network expands to serve giants like Microsoft and OpenAI. Yet the company sits atop a mountain of debt and mounting lease obligations that threaten near-term cash flow. With about $11 billion of debt and $1.9 billion in 2024 revenue, 2025 guidance hinges on jumbo capex (expected at $20-$23 billion) and long-term leases totaling roughly $34 billion through 2028. The balance sheet also shows current liabilities of $7.6 billion, raising the risk that unprofitable customers or construction delays could trigger cancellations or prepayments. In essence, CoreWeave's earnings trajectory and leverage may be a bellwether for the AI-infrastructure boom and its funding needs.
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In
Previous Story

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside
Next Story

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Go toTop